Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 9:55 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 20,632 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Dysfunction Clear all
Completed Phase 2 Interventional Results available

Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma

NCT00290511
View directory record Official record
Conditions
Lymphoma
Interventions
Fludarabine, Mitoxantrone, Rituximab, Zevalin, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Nov 3, 2026, 9:55 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

NCT01544348
View directory record Official record
Conditions
Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
Interventions
Placebo, Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous, MEDI4212 60 mg Subcutaneous, MEDI4212 150 mg Subcutaneous, MEDI4212 300 mg Subcutaneous, MEDI4212 300 mg Intravenous
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
7
States / cities
Cypress, California • Glendale, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Nov 3, 2026, 9:55 PM EST
Completed Phase 2 Interventional Results available

Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis

NCT01093326
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ponesimod 10 mg, Ponesimod 20 mg, Ponesimod 40 mg
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
16
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Nov 3, 2026, 9:55 PM EST
Completed Phase 2 Interventional

Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension

NCT03814317
View directory record Official record
Conditions
Sarcoidosis, Precapillary Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Inhaled Treprostinil
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Nov 3, 2026, 9:55 PM EST
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

NCT02269917
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1
Interventions
D/C/F/TAF, Boosted Protease Inhibitor (bPI), FTC/TDF
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
38
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Nov 3, 2026, 9:55 PM EST
Completed Not applicable Interventional Results available

Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX

NCT00360685
View directory record Official record
Conditions
Mucositis, Graft-versus-host Disease
Interventions
Tac+MTX, TAC + MMF
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
Not listed
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Nov 3, 2026, 9:55 PM EST
Completed Not applicable Interventional

Intervention for Improving Asthma Care for Minority Children in Head Start

NCT00094276
View directory record Official record
Conditions
Asthma, Lung Diseases
Interventions
Facilitated Asthma Communication Intervention (FACI), Breathmobile intervention
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
2 Years to 6 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Nov 3, 2026, 9:55 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Metabolic and Psychological Changes Associated With Menopause Among Women With HIV

NCT01142817
View directory record Official record
Conditions
HIV Infections, Menopause
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 52 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Nov 3, 2026, 9:55 PM EST
Completed No phase listed Observational

Influences on HIV Infected Subjects' Willingness to Participate in Research and Ability to Give Informed Consent

NCT00001717
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 3, 2026, 9:55 PM EST
Terminated No phase listed Observational

Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms

NCT00919217
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Nov 3, 2026, 9:55 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Nutrition and Body Composition in Acute Lymphoblastic Leukemia

NCT01317940
View directory record Official record
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Vitamin D Deficiency
Interventions
Vitamin D and Calcium Citrate
Dietary Supplement
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
10 Years to 29 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Nov 3, 2026, 9:55 PM EST
Completed Phase 3 Interventional

BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients

NCT03394989
View directory record Official record
Conditions
Bronchial Asthma
Interventions
Fluticasone propionate/salmeterol 100/50 µg, Placebo, Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT
Drug · Other
Lead sponsor
Cipla Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Nov 3, 2026, 9:55 PM EST
Completed Phase 2 Interventional

Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV

NCT00672191
View directory record Official record
Conditions
HIV Infections
Interventions
AGS-004
Biological
Lead sponsor
Argos Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Nov 3, 2026, 9:55 PM EST
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic Leukemia

NCT00002838
View directory record Official record
Conditions
Leukemia
Interventions
Filgrastim (G-CSF), Cyclophosphamide, Fludarabine Phosphate, Peripheral Blood Stem Cell Transplantation
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Nov 3, 2026, 9:55 PM EST
Completed Not applicable Interventional

Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery

NCT02955043
View directory record Official record
Conditions
Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Lymphoid Leukemia, Myeloid Leukemia, Myelodysplastic Syndromes, Multiple Myeloma
Interventions
Behavioral techniques
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 74 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Nov 3, 2026, 9:55 PM EST
Completed Phase 2 Interventional

Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis

NCT05363891
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Natrunix, Placebo
Drug
Lead sponsor
XBiotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
26
States / cities
Covina, California • Encino, California • Rancho Mirage, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Nov 3, 2026, 9:55 PM EST
Terminated No phase listed Observational

Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy

NCT01319526
View directory record Official record
Conditions
Lymphoma, Nonneoplastic Condition
Interventions
DNA analysis, RNA analysis, laboratory biomarker analysis
Genetic · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Nov 3, 2026, 9:55 PM EST
Completed Phase 1 Interventional

Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome

NCT00000726
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Nov 3, 2026, 9:55 PM EST
Completed No phase listed Observational

Comparison of Gut Microbiota, Inflammation and Symptoms Following Allogeneic HSCT

NCT02398708
View directory record Official record
Conditions
Graft vs Host Disease, Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation
Interventions
Questionnaires, Blood Sample, Stool Sample, Clinical data
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Nov 3, 2026, 9:55 PM EST
Terminated Phase 3 Interventional Results available

On Open-Label Study in Participants With Systemic Lupus Erythematosus

NCT01488708
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
Interventions
LY2127399, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Nov 3, 2026, 9:55 PM EST
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

NCT07086976
View directory record Official record
Conditions
Autoimmune Haemolytic Anaemia
Interventions
rilzabrutinib, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
27
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 3, 2026, 9:55 PM EST
Not listed Phase 4 Interventional

Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment

NCT00005017
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz, Lamivudine, Stavudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 9:55 PM EST
Completed Phase 3 Interventional Results available

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease

NCT00348140
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
49
States / cities
Sun City, Arizona • Tucson, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Nov 3, 2026, 9:55 PM EST